| 9.01 -0.14 (-1.53%) | 05-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 11.65 | 1-year : | 13.6 |
| Resists | First : | 9.97 | Second : | 11.65 |
| Pivot price | 8.78  |
|||
| Supports | First : | 8.66 | Second : | 7.86 |
| MAs | MA(5) : | 8.64 |
MA(20) : | 9 |
| MA(100) : | 9.28 |
MA(250) : | 10.67 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 52.8 |
D(3) : | 38.4 |
| RSI | RSI(14): 51.8 |
|||
| 52-week | High : | 16.44 | Low : | 6.23 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ OCUL ] has closed below upper band by 39.9%. Bollinger Bands are 16.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.28 - 9.32 | 9.32 - 9.35 |
| Low: | 8.84 - 8.91 | 8.91 - 8.95 |
| Close: | 8.92 - 9.01 | 9.01 - 9.07 |
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Thu, 28 May 2026
Ocular Therapeutix chief scientific officer sells $24,747 in stock - Investing.com
Thu, 28 May 2026
Automatic tax-driven sale and trust transfer by Ocular (OCUL) insider - Stock Titan
Thu, 28 May 2026
Ocular Therapeutix (NASDAQ: OCUL) CDO executes 2,967-share tax sell-to-cover trade - Stock Titan
Thu, 28 May 2026
Ocular Therapeutix (OCUL) CSO sells 3,018 shares to cover RSU taxes - Stock Titan
Thu, 28 May 2026
Ocular Therapeutix (NASDAQ: OCUL) CSO auto-sells 1,858 shares for tax obligations - Stock Titan
Tue, 26 May 2026
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 219 (M) |
| Shares Float | 217 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 95.7 (%) |
| Shares Short | 24,790 (K) |
| Shares Short P.Month | 25,190 (K) |
| EPS | -1.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.02 |
| Profit Margin | 0 % |
| Operating Margin | -865.5 % |
| Return on Assets (ttm) | -32.9 % |
| Return on Equity (ttm) | -68.6 % |
| Qtrly Rev. Growth | 0.8 % |
| Gross Profit (p.s.) | -0.8 |
| Sales Per Share | 0.23 |
| EBITDA (p.s.) | -1.35 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -226 (M) |
| Levered Free Cash Flow | -149 (M) |
| PE Ratio | -6.26 |
| PEG Ratio | 0 |
| Price to Book value | 2.97 |
| Price to Sales | 37.9 |
| Price to Cash Flow | -8.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|